Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReview
Open Access

Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy

HIROSHI MASUDA
Anticancer Research January 2023, 43 (1) 305-309; DOI: https://doi.org/10.21873/anticanres.16164
HIROSHI MASUDA
Department of Urology, Chiba Rosai Hospital, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hrsmasuda@yahoo.co.jp
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Androgen deprivation therapy (ADT) is the major treatment for advanced prostate cancer (PCa). Although ADT has been shown to improve oncological outcomes against PCa, it can also induce various adverse events, such as loss of libido, gynecomastia, fatigue, hot flashes, anemia, obesity, insulin resistance, dyslipidemia, cardiovascular events, and acute kidney injury (AKI). ADT reduces testosterone levels; consequently, ADT may antagonize the vasodilatory effects of testosterone on renal blood vessels, which could negatively affect renal tubular function. However, the renal impairment due to ADT is transient; i.e., it improves after the discontinuation of ADT. The recovery of serum testosterone levels may contribute to the amelioration of renal impairment induced by ADT. Serum testosterone levels are probably implicated in these changes, but the mechanism has not been studied in detail. With regard to the preservation of renal function and the anti-cancer effect of PCa, intermittent ADT may be a useful treatment for PCa. This is a review of the recent reports on the mechanism, current status, and prevention of renal impairment induced by ADT; future prospects in this field are also discussed.

Key Words:
  • Renal impairment
  • androgen deprivation therapy
  • prostate cancer
  • estimated glomerular filtration rate
  • review

Huggins and Hodges demonstrated that prostate cancer (PCa) was an androgen-dependent disease and androgen deprivation therapy (ADT) was the effective treatment in patients with advanced PCa (1). Since their study, both medical and surgical ADT have been performed to treat patients with clinically localized or metastatic prostate cancer (mPCa) (2, 3). In randomized trials, ADT has been shown to improve overall survival in cases of locally advanced (4, 5) and lymph node-positive PCa (6), and after surgery for lymph node-positive PCa (7).

Although ADT has been shown to be effective and useful treatment against PCa progression, numerous recognized adverse events of ADT, which include loss of libido, gynecomastia, fatigue, hot flashes (HF), osteoporosis, insulin resistance, dyslipidemia, cardiovascular events, and acute kidney injury (AKI), occur during such treatment (8, 9). Recently, it was reported that in newly diagnosed non-mPCa patients, ADT usage is significantly associated with an increased risk of AKI (10). Glomerular function may be disrupted in the renal system by hyperglycemia and dyslipidemia, which dilate and thicken the interstitial tubular membranes (11). Moreover, it is suggested that ADT may antagonize the vasodilatory effects of testosterone on renal blood vessels (12), simultaneously, it may create estrogen deficiency and negatively affect renal tubular function (13). Through these mechanisms, ADT may increase the risk of AKI. Serum testosterone levels are probably implicated in these changes, but the mechanism has not been studied in detail. Although there have been several meta-analyses of randomized studies of ADT and its cardiovascular outcomes (14-17), there have not been any such analyses of randomized studies of the link between ADT and AKI. Therefore, retrospective studies are critical for assessing renal impairment associated with ADT in PCa patients.

Shere et al. reported that the incidence of AKI at two years after diagnosis was 10.5% in the radiotherapy (RT) + ADT group and 7.9% in the RT group (p<0.01) (18). Multivariate analysis confirmed that ADT usage was significantly associated with an increased risk of any AKI. ADT was also found to be significantly associated with an increased risk of mild AKI and moderate AKI, but not severe AKI (p=0.11). Thus, they suggested that the use of ADT is associated with an increased risk of AKI in patients receiving definitive RT for PCa. AKI may also cause chronic kidney disease (CKD), which may eventually require hemodialysis. Hence, it is necessary to consider AKI as a complication that impacts the patients’ quality of life (QOL).

This is a review of the literature on the mechanisms, current status, and prevention of renal impairment elicited by ADT. strategies to prevent adverse events are also discussed.

ADT for PCa and AKI

Criteria for AKI. In 2012, the Kidney Disease Improving Global Outcomes (KDIGO) criteria were suggested, which integrated the Risk, Injury, Failure, Loss, and End-stage renal disease (RIEFLE) and Acute Kidney Injury Network (AKIN) criteria. The KDIGO criteria for AKI include any one of the following: #1) an increasing level in the serum creatinine (sCr) by ≥0.3 mg/dl within 48 hours, #2) an increasing level in the sCr to ≥1.5 times compared to the baseline within the preceding 7 days, and #3) a urine volume of <0.5 ml/kg/h for 6 h. The severity of AKI is categorized from stage 1 to 3 according to the patient’s sCr level or urine output volume by the KDIGO criteria (19). Since few studies in the literature fulfill the aforementioned definition, in this review the term “renal impairment” was used instead of “AKI”. Moreover, it has been reported that ADT-induced renal impairment is transient, as it tends to improve after the discontinuation of ADT (20). Therefore, in this review, the term “renal impairment” was used rather than “renal dysfunction”.

Parameters Used to Investigate Renal Function

Utility of the rate of change in the estimated glomerular filtration rate (ΔeGFR). With regard to the evaluation of renal function, there have been several reports using the rate of change in the eGFR (ΔeGFR) rather than the level of eGFR itself. In addition, it has been reported that the mean rate of decline in the eGFR in healthy Japanese aged ≥40 years was 0.36 ml/min/1.73 m2/year (21). The value of the decline in eGFR is determined. Hence, individual eGFR values may be compared. It may be useful to compare previously reported data with the data gained from these new studies. Recently, the concept of CKD became widespread in Japan. The eGFR has been used to classify CKD. We should use the eGFR more frequently in the evaluation of renal function. The ΔeGFR seems to be a useful tool for monitoring changes in renal function over time, and its use is expected to become more widespread.

Impact of decreased testosterone levels on renal function. In the renal system, metabolic changes associated with ADT, such as dyslipidemia and hyperglycemia, may disrupt glomerular function by expanding and thickening of the interstitial tubular membrane (11). In addition, ADT may antagonize the vasodilatory effects of testosterone on renal blood vessels (12). Through these mechanisms, ADT may induce AKI. It was reported that serum testosterone levels increased after the discontinuation of ADT (22), and the recovery of serum testosterone levels may be associated with improvements in renal function. Serum testosterone levels may be a critical factor on renal function during ADT. There have been reported that the renal impairment seen in Japanese patients during ADT for PCa is temporary; i.e., renal function tends to recover after the discontinuation of ADT (20). Lapi et al. investigated the United Kingdom Clinical Practice Research Datalink and identified 10,250 males that had been newly diagnosed with non-mPCa in 2013. The crucial finding was that the use of ADT within the previous 90 days was associated with a significantly increased risk of AKI compared with that seen in males that had never been exposed to ADT [odds ratio (OR)=2.48; 95%CI=1.61-3.82]. All treatments of prostate cancer, including the use of luteinizing hormone-releasing hormone agonists, estrogen, combined androgen blockade, and other combination therapies significantly increased the risk of AKI. In addition, oral antiandrogens and bilateral orchiectomy were also shown to be associated with an increased risk of AKI, though this was not significant (10). Gandaglia et al. have reported that the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p<0.001). Multivariate analyses revealed that the administration of gonadotropin-releasing hormone agonists [hazard ratio (HR)=1.24; 95% confidence interval (CI)=1.18-1.31; p<0.001], but not bilateral orchiectomy (HR=1.11; 95%CI=0.96-1.29; p=0.1), was associated with an increased risk of experiencing AKI. In addition, Gandaglia et al. demonstrated that the highest risk of AKI occurred within the first third of the ADT treatment period (<386 days) (23). Also, it was indicated that about one third of people who took bicalutamide (Bic) for 1-6 months experienced renal failure (24). Moreover, Peng et al. have reported the renal damage elicited by bicalutamide therapy as evidenced in a cell model (25).

Risk factors for renal impairment. Recently, it was reported that hypertension is an independent risk factor for renal impairment after 6 months of ADT. Therefore, PCa patients that are treated with ADT should periodically perform not only prostate specific antigen (PSA) but also renal function and urinary salt intake examinations (26). Although it was not considered to be a risk factor of AKI, it was reported that the presence/absence of HF after ADT influenced renal function in Japanese PCa patients treated with RT (27). This report is very interesting. In the future, it is expected that the association between the occurrence of HF and renal impairment will be elucidated. Moreover, it has been reported that renal function improves after the discontinuation of ADT, and decreased serum testosterone levels may be a risk factor for renal impairment. It may be worth paying attention to changes in serum testosterone levels.

Period of renal impairment. In a retrospective study, it was reported that renal impairment induced by ADT for PCa occurs from 1 month of ADT (26). Moreover, it was confirmed that renal impairment was worst after 3 months of ADT. Masuda et al. have shown that renal impairment persisted for 24 months during the ADT with radiation therapy (RT) in Japanese patients with high-risk prostate cancer, but renal function tended to improve after the discontinuation of ADT (27). In addition, they concluded that the renal impairment caused by 24 months of ADT was transient.

Permanence of renal impairment. Whether the renal impairment induced by ADT is transient or permanent is extremely important because if the renal impairment continues to progress, it will advance to end-stage renal disease (ESRD), and hemodialysis will be required in the future. ESRD negatively impacts the QOL of patients by adversely affecting their social, financial, and psychological status. In addition to patients physical, functional, metabolic, social, and mental status, the general QOL of patients may also be impaired (28, 29). It was reported that the health-related quality of life (HRQOL) of dialysis patients is usually worse than that of the age-matched subjects from the general population because of the typically high burden of comorbidities and complications of associated with ESRD (30). Hence, although the treatment of PCa with ADT could be curative, a subsequent requirement for hemodialysis, which is harmful to QOL, should be avoided. A previous study suggested that renal function may improve after the discontinuation of ADT in Japanese high-risk PCa patients (20). Therefore, the recovery of testosterone levels may be related to improvements in renal function after the discontinuation of ADT. However, the reason for this is unclear.

Future Perspectives

Renal impairment due to ADT is an important adverse event. Therefore, it is suggested that periodic PSA levels, renal function, and urinary salt intake examinations are necessary during ADT. The discontinuation of ADT may be expected to result in the recovery of testosterone levels and improvements in renal function. In this regard, bipolar androgen therapy (BAT) is assumed to be an effective treatment that both preserves renal function and achieves cancer control. BAT has been demonstrated to be effective against castration-resistant PCa (CRPC) (31). In CRPC patients, BAT may contribute to the preservation and improvement of renal function. There has also been a report about BAT for androgen ablation-naïve PCa (32). Approximately 60% of patients who received BAT maintained a PSA of <4.0 ng/ml, and the objective response rate was about 80%. In addition, BAT may improve the QOL of males treated with ADT. Furthermore, the recovery of serum testosterone levels observed after the discontinuation of ADT for PCa may be associated with improvements in renal function. Intermittent ADT (IAD) may be considered as one of endocrine treatments for PCa in order to preserve renal function, because it may recover serum testosterone levels. However, there have not been any reports concerning the link between AKI and IAD. Although prospective studies are essential for clarifying the relationship between ADT and AKI, until now there have not been any such studies. Therefore, when examining the association between ADT and renal impairment, we have to rely on retrospective studies, which provide low levels of evidence. Murphy et al. have reported that AKI after esophageal cancer is associated with dyslipidemia and dyslipidemia was one of the independent preoperative factors predicting AKI (p=0.002) (33). Dyslipidemia may be a risk factor for exacerbating renal function. Considering the abnormal lipid metabolism induced by ADT, treatment for dyslipidemia may prevent ADT-induced renal impairment. Moreover, Wu et al. have reported that the use of statin is independently associated with reduced risks of 1-year in patients with dialysis requiring AKI (34). To verify the protective effect of statin on renal function, it will be necessary to investigate the assessment of renal function for patients administered statins in PCa patients treated with ADT. In the investigation of renal impairment, the ΔeGFR seems to be a useful and effective tool. Consequently, its use is expected to become more widespread in the future.

Conclusion

Although ADT is associated with an increased risk of renal impairment, such changes may be considered to be transient, since the discontinuation of ADT leads to the recovery of renal impairment. Testosterone is probably implicated in these changes, but the mechanism has not been studied in detail. During ADT, BAT or IAD should be considered as ways of protecting renal function. With regard to renal dysfunction due to ADT, the term “renal impairment” should be used instead of “AKI”.

Footnotes

  • Conflicts of Interest

    The Author declares no conflicts of interest in relation to this study.

  • Received October 16, 2022.
  • Revision received November 1, 2022.
  • Accepted November 2, 2022.
  • Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Huggins C and
    2. Hodges CV
    : Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4): 232-240, 1972. PMID: 4625049. DOI: 10.3322/canjclin.22.4.232
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sharifi N,
    2. Gulley JL and
    3. Dahut WL
    : Androgen deprivation therapy for prostate cancer. JAMA 294(2): 238-244, 2005. PMID: 16014598. DOI: 10.1001/jama.294.2.238
    OpenUrlCrossRefPubMed
  3. ↵
    1. Shahinian VB,
    2. Kuo YF,
    3. Freeman JL,
    4. Orihuela E and
    5. Goodwin JS
    : Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8): 1615-1624, 2005. PMID: 15742331. DOI: 10.1002/cncr.20955
    OpenUrlCrossRefPubMed
  4. ↵
    1. Denham JW,
    2. Steigler A,
    3. Lamb DS,
    4. Joseph D,
    5. Turner S,
    6. Matthews J,
    7. Atkinson C,
    8. North J,
    9. Christie D,
    10. Spry NA,
    11. Tai KH,
    12. Wynne C and
    13. D’Este C
    : Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12(5): 451-459, 2011. PMID: 21440505. DOI: 10.1016/S1470-2045(11)70063-8
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bolla M,
    2. Gonzalez D,
    3. Warde P,
    4. Dubois JB,
    5. Mirimanoff RO,
    6. Storme G,
    7. Bernier J,
    8. Kuten A,
    9. Sternberg C,
    10. Gil T,
    11. Collette L and
    12. Pierart M
    : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337(5): 295-300, 1997. PMID: 9233866. DOI: 10.1056/NEJM199707313370502
    OpenUrlCrossRefPubMed
  6. ↵
    1. Lawton CA,
    2. Winter K,
    3. Grignon D and
    4. Pilepich MV
    : Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23(4): 800-807, 2005. PMID: 15681524. DOI: 10.1200/JCO.2005.08.141
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Messing EM,
    2. Manola J,
    3. Sarosdy M,
    4. Wilding G,
    5. Crawford ED and
    6. Trump D
    : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24): 1781-1788, 1999. PMID: 10588962. DOI: 10.1056/NEJM199912093412401
    OpenUrlCrossRefPubMed
  8. ↵
    1. Perlmutter MA and
    2. Lepor H
    : Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 9 Suppl 1: S3-S8, 2007. PMID: 17387371.
    OpenUrlPubMed
  9. ↵
    1. Levine GN,
    2. D’Amico AV,
    3. Berger P,
    4. Clark PE,
    5. Eckel RH,
    6. Keating NL,
    7. Milani RV,
    8. Sagalowsky AI,
    9. Smith MR,
    10. Zakai N and American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association
    : Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121(6): 833-840, 2010. PMID: 20124128. DOI: 10.1161/CIRCULATIONAHA.109.192695
    OpenUrlFREE Full Text
  10. ↵
    1. Lapi F,
    2. Azoulay L,
    3. Niazi MT,
    4. Yin H,
    5. Benayoun S and
    6. Suissa S
    : Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 310(3): 289-296, 2013. PMID: 23860987. DOI: 10.1001/jama.2013.8638
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kambham N,
    2. Markowitz GS,
    3. Valeri AM,
    4. Lin J and
    5. D’Agati VD
    : Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59(4): 1498-1509, 2001. PMID: 11260414. DOI: 10.1046/j.1523-1755.2001.0590041498.x
    OpenUrlCrossRefPubMed
  12. ↵
    1. Molinari C,
    2. Battaglia A,
    3. Grossini E,
    4. Mary DA,
    5. Vassanelli C and
    6. Vacca G
    : The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543(Pt 1): 365-372, 2002. PMID: 12181306. DOI: 10.1113/jphysiol.2002.022756
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hutchens MP,
    2. Fujiyoshi T,
    3. Komers R,
    4. Herson PS and
    5. Anderson S
    : Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo. Am J Physiol Renal Physiol 303(3): F377-F385, 2012. PMID: 22622457. DOI: 10.1152/ajprenal.00354.2011
    OpenUrlCrossRefPubMed
  14. ↵
    1. Azoulay L,
    2. Yin H,
    3. Benayoun S,
    4. Renoux C,
    5. Boivin JF and
    6. Suissa S
    : Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60(6): 1244-1250, 2011. PMID: 21908097. DOI: 10.1016/j.eururo.2011.08.041
    OpenUrlCrossRefPubMed
    1. Nanda A,
    2. Chen MH,
    3. Braccioforte MH,
    4. Moran BJ and
    5. D’Amico AV
    : Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302(8): 866-873, 2009. PMID: 19706860. DOI: 10.1001/jama.2009.1137
    OpenUrlCrossRefPubMed
    1. Albertsen PC,
    2. Klotz L,
    3. Tombal B,
    4. Grady J,
    5. Olesen TK and
    6. Nilsson J
    : Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3): 565-573, 2014. PMID: 24210090. DOI: 10.1016/j.eururo.2013.10.032
    OpenUrlCrossRefPubMed
  15. ↵
    1. D’Amico AV,
    2. Denham JW,
    3. Crook J,
    4. Chen MH,
    5. Goldhaber SZ,
    6. Lamb DS,
    7. Joseph D,
    8. Tai KH,
    9. Malone S,
    10. Ludgate C,
    11. Steigler A and
    12. Kantoff PW
    : Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17): 2420-2425, 2007. PMID: 17557956. DOI: 10.1200/JCO.2006.09.3369
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sherer MV,
    2. Deka R,
    3. Salans MA,
    4. Nelson TJ,
    5. Sheridan P and
    6. Rose BS
    : Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy. Prostate Cancer Prostatic Dis, 2021. PMID: 34811501. DOI: 10.1038/s41391-021-00415-3
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kellum JA,
    2. Lameire N,
    3. Aspelin P,
    4. Barsoum RS,
    5. Burdmann EA,
    6. Goldstein SL,
    7. Herzog CA,
    8. Joannidis M,
    9. Kribben A,
    10. Levey AS,
    11. MacLeod AM,
    12. Mehta RL,
    13. Murray PT,
    14. Naicker S,
    15. Opal SM,
    16. Schaefer F,
    17. Schetz M and
    18. Uchino S
    : Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO Clinical Practice Guideline for acute kidney injury. Kidney Int Suppl 2: 1-138, 2012. DOI: 10.1038/kisup.2012.1
    OpenUrlCrossRefPubMed
  18. ↵
    1. Masuda H,
    2. Fujimoto A,
    3. Kanesaka M,
    4. Hou K,
    5. Suyama T,
    6. Araki K,
    7. Kojima S and
    8. Naya Y
    : Renal function improves after the discontinuation of androgen deprivation therapy in Japanese patients with prostate cancer. Anticancer Res 41(9): 4443-4446, 2021. PMID: 34475067. DOI: 10.21873/anticanres.15252
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Imai E,
    2. Horio M,
    3. Yamagata K,
    4. Iseki K,
    5. Hara S,
    6. Ura N,
    7. Kiyohara Y,
    8. Makino H,
    9. Hishida A and
    10. Matsuo S
    : Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 31(3): 433-441, 2008. PMID: 18497462. DOI: 10.1291/hypres.31.433
    OpenUrlCrossRefPubMed
  20. ↵
    1. Tunn UW,
    2. Canepa G,
    3. Kochanowsky A and
    4. Kienle E
    : Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 15(3): 296-302, 2012. PMID: 22733160. DOI: 10.1038/pcan.2012.12
    OpenUrlCrossRefPubMed
  21. ↵
    1. Gandaglia G,
    2. Sun M,
    3. Hu JC,
    4. Novara G,
    5. Choueiri TK,
    6. Nguyen PL,
    7. Schiffmann J,
    8. Graefen M,
    9. Shariat SF,
    10. Abdollah F,
    11. Briganti A,
    12. Montorsi F,
    13. Trinh QD and
    14. Karakiewicz PI
    : Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 66(6): 1125-1132, 2014. PMID: 24495466. DOI: 10.1016/j.eururo.2014.01.026
    OpenUrlCrossRefPubMed
  22. ↵
    1. eHealthMe personalized health information
    . Casodex and Kidney failure – from FDA reports [Online]. Available at: http://www.ehealthme.com/ds/casodex/kidney%20failure/ [Last accessed on April 12, 2018]
  23. ↵
    1. Peng CC,
    2. Chen CY,
    3. Chen CR,
    4. Chen CJ,
    5. Shen KH,
    6. Chen KC and
    7. Peng RY
    : Renal damaging effect elicited by bicalutamide therapy uncovered multiple action mechanisms as evidenced by the cell model. Sci Rep 9(1): 3392, 2019. PMID: 30833616. DOI: 10.1038/s41598-019-39533-3
    OpenUrlCrossRefPubMed
  24. ↵
    1. Masuda H,
    2. Sugiura M,
    3. Hou K,
    4. Araki K,
    5. Kojima S and
    6. Naya Y
    : Impact of hypertension on early renal dysfunction in Japanese prostate cancer patients treated with androgen deprivation therapy. Cancer Diagn Progn 1(3): 179-183, 2021. PMID: 35399311. DOI: 10.21873/cdp.10024
    OpenUrlCrossRefPubMed
  25. ↵
    1. Masuda H,
    2. Mikami K,
    3. Otsuka K,
    4. Hou K,
    5. Suyama T,
    6. Araki K,
    7. Kojima S and
    8. Naya Y
    : The association between hot flashes and renal dysfunction after androgen deprivation therapy with radiotherapy in Japanese patients with high-risk prostate cancer. In Vivo 35(6): 3489-3493, 2021. PMID: 34697186. DOI: 10.21873/invivo.12650
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Al Wakeel J,
    2. Al Harbi A,
    3. Bayoumi M,
    4. Al-Suwaida K,
    5. Al Ghonaim M and
    6. Mishkiry A
    : Quality of life in hemodialysis and peritoneal dialysis patients in Saudi Arabia. Ann Saudi Med 32(6): 570-574, 2012. PMID: 23396018. DOI: 10.5144/0256-4947.2012.570
    OpenUrlCrossRefPubMed
  27. ↵
    1. Grzegorzewska AE,
    2. Izdebska A,
    3. Niepolski L,
    4. Warchoł W and
    5. Jagodziński PP
    : Self-reported physical activity, quality of life, and psychological status in relation to plasma 25-hydroxyvitamin D concentration in patients treated with hemodialysis. Kidney Blood Press Res 41(6): 886-900, 2016. PMID: 27871082. DOI: 10.1159/000452585
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kim JY,
    2. Kim B,
    3. Park KS,
    4. Choi JY,
    5. Seo JJ,
    6. Park SH,
    7. Kim CD and
    8. Kim YL
    : Health-related quality of life with KDQOL-36 and its association with self-efficacy and treatment satisfaction in Korean dialysis patients. Qual Life Res 22(4): 753-758, 2013. PMID: 22638994. DOI: 10.1007/s11136-012-0203-x
    OpenUrlCrossRefPubMed
  29. ↵
    1. Schweizer MT,
    2. Antonarakis ES,
    3. Wang H,
    4. Ajiboye AS,
    5. Spitz A,
    6. Cao H,
    7. Luo J,
    8. Haffner MC,
    9. Yegnasubramanian S,
    10. Carducci MA,
    11. Eisenberger MA,
    12. Isaacs JT and
    13. Denmeade SR
    : Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 7(269): 269ra2, 2015. PMID: 25568070. DOI: 10.1126/scitranslmed.3010563
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Schweizer MT,
    2. Wang H,
    3. Luber B,
    4. Nadal R,
    5. Spitz A,
    6. Rosen DM,
    7. Cao H,
    8. Antonarakis ES,
    9. Eisenberger MA,
    10. Carducci MA,
    11. Paller C and
    12. Denmeade SR
    : Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: results from the phase II BATMAN study. Prostate 76(13): 1218-1226, 2016. PMID: 27338150. DOI: 10.1002/pros.23209
    OpenUrlCrossRefPubMed
  31. ↵
    1. Murphy CF,
    2. Dunne T,
    3. Elliott JA,
    4. Kamarajah SK,
    5. Leighton J,
    6. Evans RPT,
    7. Bundred J,
    8. King S,
    9. Ravi N,
    10. Donohoe CL,
    11. Griffin SM,
    12. Griffiths EA,
    13. Phillips AW and
    14. Reynolds JV
    : Acute kidney injury after esophageal cancer surgery: incidence, risk factors, and impact on oncologic outcomes. Ann Surg 275(5): e683-e689, 2022. PMID: 32740248. DOI: 10.1097/SLA.0000000000004146
    OpenUrlCrossRefPubMed
  32. ↵
    1. Wu CL,
    2. Kor CT,
    3. Chang CC,
    4. Chiu PF,
    5. Tarng DC and
    6. Hsu CC
    : Association of statin use with mortality after dialysis-requiring acute kidney injury: a population-based cohort study. Mayo Clin Proc 93(10): 1474-1483, 2018. PMID: 30286832. DOI: 10.1016/j.mayocp.2018.05.034
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (1)
Anticancer Research
Vol. 43, Issue 1
January 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
HIROSHI MASUDA
Anticancer Research Jan 2023, 43 (1) 305-309; DOI: 10.21873/anticanres.16164

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
HIROSHI MASUDA
Anticancer Research Jan 2023, 43 (1) 305-309; DOI: 10.21873/anticanres.16164
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • ADT for PCa and AKI
    • Parameters Used to Investigate Renal Function
    • Future Perspectives
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Intramedullary Spinal Cord Metastases from Breast Cancer: A Systematic Review
  • The Latest Treatments for Cancer Cachexia: An Overview
  • Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies
Show more Review

Similar Articles

Keywords

  • Renal impairment
  • androgen deprivation therapy
  • prostate cancer
  • estimated glomerular filtration rate
  • review
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire